Blood levels of carbonic anhydrase 9 correlate with clear cell renal cell carcinoma activity

被引：0

作者：

Hulick P. ^{[1
]}

Zimmer M. ^{[1
]}

Margulis V. ^{[7
]}

Skates S. ^{[2
]}

Hamel M. ^{[1
]}

Dahl D.M. ^{[3
]}

Michaelson D.M. ^{[1
]}

Liebermann T. ^{[4
]}

Signoretti S. ^{[5
]}

Carney W. ^{[6
]}

Wood C. ^{[7
]}

Iliopoulos O. ^{[1
]}

机构：

[1] Massachusetts General Hospital, Cancer Center, Boston, MA 02114

[2] Department of Biostatistics, Massachusetts General Hospital, Boston, MA

[3] Department of Urology, Massachusetts General Hospital, Boston, MA

[4] Beth Israel Deaconess Medical Center, Boston, MA

[5] Department of Pathology, Brigham and Women's Hospital, Boston, MA

[6] Siemens Diagnostics Inc., Boston, MA

[7] Department of Urology, MD Anderson Cancer Center, Houston, TX

来源：

Clinical Proteomics | 2009年 / 5卷 / 1期

关键词：

Angiogenesis; Carbonic anhydrase 9; Circulating biomarker; Hypoxia inducible factor; Renal cell carcinoma; VHL;

D O I：

10.1007/s12014-008-9012-1

中图分类号：

学科分类号：

摘要：

Introduction: Biomarkers for early detection of renal cell carcinoma (RCC) may help diagnose minimal residual disease in patients at risk for RCC, can guide anti-angiogenic therapy, or may help identify candidates for adjuvant treatment. In this study, we investigated whether blood levels of carbonic anhydrase 9 (CA9) correlate with RCC tumor burden and therefore disease activity. Methods: CA9 is a von Hippel-Lindau-hypoxia inducible factor target upregulated in clear cell RCC. We used an anti-CA9 antibody (M75)-based enzyme-linked immunosorbent assay test to measure CA9 levels in blood obtained before and after nephrectomy for clinically localized disease in patients with: (1) clear cell RCC, (2) papillary and chromophobe RCC or oncocytoma, or (3) benign kidney lesions, and we compared these samples to blood drawn from normal control individuals. Results: We observed a significant (p∈<∈0.006) decrease in the blood levels of CA9, after nephrectomy for localized disease, in the majority of patients with clear cell RCC (57%). In contrast, patients with nonclear cell RCC, benign disease, or those having undergone debulking nephrectomy for metastatic disease did not have a decrease in CA9 blood levels after nephrectomy. Preliminary longitudinal follow up measurements of CA9 levels in a small group of patients indicated that rising CA9 levels may correlate with disease progression. Conclusions: Plasma CA9 levels correlate with disease activity in a subset of clear cell RCC patients and should be considered in future multiplex RCC biomarker development algorithms. © 2008 Humana Press.

引用

页码：37 / 45

页数：8

共 26 条

[1]

Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J., Cancer statistics, 2007, CA Cancer J Clin, 57, pp. 43-66, (2007)

[2]

Iliopoulos O., Molecular biology of renal cell cancer and the identification of therapeutic targets, Journal of Clinical Oncology, 24, 35, pp. 5593-5600, (2006)

[3]

Motzer R.J., Bander N.H., Nanus D.M., Medical progress: Renal-cell carcinoma, New England Journal of Medicine, 335, 12, pp. 865-875, (1996)

[4]

Brugarolas J., Renal-cell carcinoma - Molecular pathways and therapies, New England Journal of Medicine, 356, 2, pp. 185-187, (2007)

[5]

Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R.M., Sorafenib in advanced clear-cell renal-cell carcinoma, New England Journal of Medicine, 356, 2, pp. 125-134, (2007)

[6]

Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., Liang C., Booth B., Chidambaram N., Morse D., Sridhara R., Garvey P., Justice R., Pazdur R., Sorafenib for the treatment of advanced renal cell carcinoma, Clinical Cancer Research, 12, 24, pp. 7271-7278, (2006)

[7]

Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., Rini B.I., Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, Journal of Clinical Oncology, 24, 1, pp. 16-24, (2006)

[8]

Motzer R.J., Hutson T.E., Tomczak P., Michaelson D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, New England Journal of Medicine, 356, 2, pp. 115-124, (2007)

[9]

Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G.H., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, New England Journal of Medicine, 356, 22, pp. 2271-2281, (2007)

[10]

Liao S.Y., Aurelio O.N., Jan K., Zavada J., Stanbridge E.J., Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney, Cancer Res, 57, pp. 2827-2831, (1997)

← 1 2 3 →